Breaking News

SPI Pharma Launches Pharmaburst 500 Site

By Kristin Brooks | January 15, 2014

Offers technical resources and information on ODT platform

SPI Pharma has launched its new Pharmaburst 500 website -- -- which is designed to assist R&D formulators and business development managers interested in the development and commercialization of orally disintegrating tablets (ODT). The site offers technical resources, including starting formulations, as well as information on SPI Pharma's ODT technology platform, taste-masking, and drug development services.
Pharmaburst is a fully formulated off-the-shelf ODT designed for direct compression tablet manufacturing. It’s currently used in more than 60 commercialized products around the world. Pharmaburst 500, the company’s latest technology platform, was granted a U.S. patent in December 2013. Pharmaburst 500 is an optimized formulation that provides robust tablets with rapid disintegration and superior organoleptic properties, according to the company.
"Orally disintegrating tablets are becoming increasingly popular due to their convenience and compliance advantages. They are becoming mainstream in a variety of prescription and OTC medications for treating pain, cough/cold, sleep disorders, GERD, and ED," said Diane Reitter, Business Manager for SPI Pharma. "SPI Pharma is uniquely positioned to support our customer's ODT development projects by offering taste-masking and drug development services along with our market leading Pharmaburst technology."
blog comments powered by Disqus
  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important